| CAS |
No.22427-39-0 |
| 中文名称 |
人参皂苷Rg1(10mM in DMSO,无菌） |
| 英文名称 |
Ginsenoside Rg1(10mM in DMSO，Sterile） |
| 分子式 |
C42H72O14 |
| 分子量 |
801.01 |
| 溶解性 |
请根据自己的实验要求使用。 |
| 外观(性状) |
无菌溶液 |
| 储存条件 |
Stroe at -20℃，6 months. |
| 靶点 |
Amyloid-β |
| 通路 |
Neuronal Signaling |
| 背景说明 |
通过降低大脑 Aβ 水平来发挥作用。Ginsenoside Rg1 减少 NF-κB 核易位。 |
| 生物活性 |
Ginsenoside Rg1 is one of the major active components of Panax ginseng. Ginsenoside Rg1 ameliorates the impaired cognitive function， displays promising effects by reducing cerebral Aβ levels. Ginsenoside Rg1 also reduces NF-κB nuclear translocation.[1-3] |
| In Vitro |
Ginsenoside Rg1 促进人牙髓细胞 (hDPC) 的增殖和分化。Ginsenoside Rg1 中 hDPC 的增殖能力显著增强 (p[3]。在脂多糖 (LPS) 刺激的 RAW264.7 细胞中，p-IκBα 和 p-p65 的水平明显高于对照组，而 PPAR-γ 水平明显较低。Ginsenoside Rg1 体外处理可抑制 IκBα 磷酸化，减少 NF-κB 核转位并上调 PPAR-γ 表达[2]。 |
| In Vivo |
在佐剂性关节炎 (AIA) 大鼠的发炎关节中，p-IκBα 和 p-p65 的水平显著高于对照组，而 PPAR-γ 水平显著降低。Ginsenoside Rg1 在体内处理可抑制 IκBα 磷酸化，减少 NF-κB 核转位并上调 PPAR-γ 表达[2]。与阿尔茨海默病 (AD) 模型组相比，Ginsenoside Rg1 (G-Rg1) 和人参皂苷 Rg2 (G-Rg2) 减少了最后两天训练的逃逸潜伏期 (p1-42 的积累。在Ginsenoside Rg1 和Ginsenoside Rg2 处理的小鼠中，在 APP/PS1 小鼠中观察到的病理异常逐渐得到改善。可见清晰的核仁和浅棕色、稀疏散在的 Aβ 沉积物[1]。 |
| 细胞实验 |
hDPCs are incubated with different concentrations of Ginsenoside Rg1 (0.1， 0.5， 2.5， 5， 10 and 20 μM) . The effects of Ginsenoside Rg1 on the proliferative ability of hDPCs are evaluated by a fibroblast colony forming test， MTT assay and flow cytometry for cell cycle. The control group， osteogenic induction group， Ginsenoside Rg1 (5 μM) group and combination group are designed， and alkaline phosphatase (ALP) activity and FQ-PCR for gene expressions of dentine sialophosphoprotein (DSPP) and dentine matrix protein 1 (DMP1) are performed to evaluate the differentiation of hDPCs[3]. |
| 动物实验 |
Mice[1] Male APP/PS1 mice， weighing 20±2 g， and male C57BL/6J mice， weighing 20±2 g， are used. The animals are maintained in an air-conditioned animal center at 23±2°C and a relative humidity of 50±10%， with a natural light-dark cycle. Food and water are available ad libitum. After acclimatization for 1 wk， the mice are divided into four groups (n=10 in each group): the normal control group， the AD model group， the Ginsenoside Rg1 group， and the Ginsenoside Rg2 group. According to the concentration-response curves， the mice in the Ginsenoside Rg1 and Ginsenoside Rg2 groups are injected intraperitoneally once daily with Ginsenoside Rg1 and Ginsenoside Rg2 (30 mg/kg)， respectively， dissolved in saline. The mice in the AD model group (APP/PS1 mice) and the normal control group (C57BL/6J nontransgenic littermates) are treated with isodose saline (0.9% w/v). All mice are treated for 1 mo before brain metabolite profiling. |
| 数据来源文献 |
[1]. Li N， et al. A UPLC/MS-based metabolomics investigation of the protective effect of ginsenosides Rg1 and Rg2 in mice with Alzheimer‘s disease. J Ginseng Res. 2016 Jan;40(1):9-17.
[2]. Wang P， et al. Effect of ginsenoside Rg1 on proliferation and differentiation of human dental pulp cells in vitro. Aust Dent J. 2012 Jun;57(2):157-65.
[3]. Zhang L， et al. Ginsenoside Rg1 attenuates adjuvant-induced arthritis in rats via modulation of PPAR-γ/NF-κB signal pathway. Oncotarget. 2017 Jul 24;8(33):55384-55393. |
| 规格 |
1ml |
| 单位 |
瓶 |
中文
英语
说明书下载
京公网安备 11011202000391号